| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 07/18/2002 | WO2001081408A3 G-protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same |
| 07/18/2002 | WO2001080847A3 Combination of carboxyalkylethers with antihypertensives and pharmaceutical use |
| 07/18/2002 | WO2001072728A3 Novel piperazine derivatives |
| 07/18/2002 | WO2001072685A3 Polyamine analogues as cytotoxic agents |
| 07/18/2002 | WO2001068142A9 Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same |
| 07/18/2002 | WO2001068065A9 Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease |
| 07/18/2002 | WO2001060400B1 Use of inhibitors of caspase-3 or caspase-activated desoxyribonuclease (cad) for treating cardiac disease |
| 07/18/2002 | WO2001051520A9 Nogo receptor-mediated blockade of axonal growth |
| 07/18/2002 | WO2001044514A3 Methods and compositions for identifying morphogenic protein analogs using morphogenic protein responsive inhibitory elements |
| 07/18/2002 | WO2001039766A3 Screening invertebrate pheromones for therapeutic activity |
| 07/18/2002 | WO2000078972A9 Regulation with binding cassette transporter protein abc1 |
| 07/18/2002 | US20020095258 System and methods for optimized drug delivery and progression of diseased and normal cells |
| 07/18/2002 | US20020095135 Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| 07/18/2002 | US20020095030 Nucleotide sequences coding preferfential polypeptides for use in the treatment of apotosis defects |
| 07/18/2002 | US20020095024 B7-related nucleic acids and polypeptides useful for immunomodulation |
| 07/18/2002 | US20020095023 Membrane protein for use in the treatment of allergies, parkinson's, alzheimer's and apoptitic defects |
| 07/18/2002 | US20020094998 Methods and compositions for treatment of ocular neovascularization and neural injury |
| 07/18/2002 | US20020094994 Pyrrolidine carboxylic Acid or ester derivatives are useful for treating alpha 4 beta 1 mediated cell adhesion |
| 07/18/2002 | US20020094987 Amide or thioamide substituted benzimidazole or quinoxaline derivatives; therapeutic utility via inhibition of tumor necrosis factor or phosphodiesterase |
| 07/18/2002 | US20020094986 Combination treatment for depression, anxiety and psychosis |
| 07/18/2002 | US20020094980 Preparing 1,1-dioxo-2-phenyl-3-carboxy-4-phenyl-1,2-benzo(e)-thiazines by a five-step process starting with a (2-(methyl-oxycarbonyl-)phenyl-sulfonamido-)benzene; alkylation; cyclization; hydroxylation; esterification and coupling |
| 07/18/2002 | US20020094979 Use of 5HT-6 antagonists |
| 07/18/2002 | US20020094960 Specifically unipolar depression, treatment-refractory depression, resistant depression, anxious depression and dysthymia; 2-sulfamatomethyltetrahydropyrans and sulfamato-methylcyclohexanes, e.g. topiramate |
| 07/18/2002 | US20020094955 Plasminogen-like polynucleotides, polypeptides, and antibodies |
| 07/18/2002 | US20020094948 To treat anemias or hemodialysis patients; individual dosage forms |
| 07/18/2002 | US20020094350 Compositions containing an active fraction isolated from scutellariae barbatae and methods of use |
| 07/18/2002 | US20020094326 Treating tissue with phosphodiesterase inhibitor compound and administering exogenous nucleic acid |
| 07/18/2002 | US20020094324 Gene therapy for restenosis using an adenoviral vector |
| 07/18/2002 | DE10102053A1 Piperazinylcarbonyl-quinoline and piperazinylcarbonyl-isoquinoline derivatives useful for treatment of e.g. schizophrenia, psychoses, depression, Parkinson's disease and Alzheimer's disease |
| 07/18/2002 | DE10102048A1 Use of active antithrombin III having endothelial cell proliferation inhibitory activity for combating diseases associated with angiogenesis, e.g. retinopathy, neuropathy, leprosy and cancer |
| 07/18/2002 | CA2436876A1 Transcriptional mediators of blood vessel development and endothelial differentiation |
| 07/18/2002 | CA2434672A1 Sfrp and peptide motifs that interact with sfrp and methods of their use |
| 07/18/2002 | CA2434543A1 Inhibition of pathological angiogenesis in vivo |
| 07/18/2002 | CA2434399A1 Method for processing dendritic cells and for activating macrophages with ru 41740 |
| 07/18/2002 | CA2434330A1 Composition for inducing islet neogenesis, containing gastrin/cck receptor ligands and egf receptor ligands |
| 07/18/2002 | CA2434274A1 N-pyridyl carboxamide derivatives and pharmaceutical compositions containing them |
| 07/18/2002 | CA2434269A1 Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms |
| 07/18/2002 | CA2434152A1 Therapeutic heterocyclic compounds |
| 07/18/2002 | CA2434015A1 Therapeutic chroman compounds |
| 07/18/2002 | CA2434006A1 Pyrrolo[2,3-d]pyrimidine and their use as purinergic receptor antagonists |
| 07/18/2002 | CA2433981A1 Mikanolide derivatives, their preparation and therapeutic uses |
| 07/18/2002 | CA2433960A1 1-dimercaptoalkylquinazolin-2,4(1h,3h)-diones as matrix metalloproteinase (mmp) inhibitors |
| 07/18/2002 | CA2433954A1 Compositions and methods for regulating receptor clustering |
| 07/18/2002 | CA2433723A1 Chemical derivatives and their use as anti-telomerase agent |
| 07/18/2002 | CA2433656A1 Hormone replacement therapy method and its administration form |
| 07/18/2002 | CA2433653A1 Regulation of lipids and/or bone density and compositions therefor |
| 07/18/2002 | CA2433652A1 Active metabolite of antifungal compound |
| 07/18/2002 | CA2433623A1 Pyridine derivatives useful as cyclooxygenase inhibitor |
| 07/18/2002 | CA2433451A1 Use of an ltb4 antagonist for the treatment and/or prevention of diseases caused by increased expression of mucin genes |
| 07/18/2002 | CA2432350A1 Method for inhibiting the expression of a target gene |
| 07/18/2002 | CA2432114A1 4-(hetero)aryl substituted indolinones |
| 07/18/2002 | CA2430588A1 Modulation of pericyte proliferation using bpi protein products or bpi inhibitors |
| 07/18/2002 | CA2429177A1 Inhibition of nf-.kappa.b by triterpene compositions |
| 07/18/2002 | CA2425625A1 Aza-and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors |
| 07/17/2002 | EP1223221A2 Recombinant vector for use in gene therapy for insulindependent diabetes mellitus and therapeutic composition thereof |
| 07/17/2002 | EP1223176A2 Peptide mutant of human ERAB/HADH2, its X-ray crystal structure, and materials and method for identification of inhibitors thereof |
| 07/17/2002 | EP1223173A2 Novel 2'-O-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof |
| 07/17/2002 | EP1223170A1 Pyrimidine-5-carboxamide compounds, process for producing the same and use thereof |
| 07/17/2002 | EP1222925A2 Kavalactone as TNF-alpha production inhibitor |
| 07/17/2002 | EP1222920A2 Mitochondria protecting agents for treating mitochondria associated diseases |
| 07/17/2002 | EP1222683A1 Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease |
| 07/17/2002 | EP1222466A2 Method to identify compounds which modulate fra-1 expression fils |
| 07/17/2002 | EP1222463A2 Allosteric sites on muscarinic receptors |
| 07/17/2002 | EP1222459A1 Crystallographic structure of the androgen receptor ligand binding domain |
| 07/17/2002 | EP1222308A1 Antiprotozoal histone acetyl transferase inhibitors |
| 07/17/2002 | EP1222302A1 Process for producing, methods and compositions of cholesterol lowering agents from higher basidiomycetes mushrooms |
| 07/17/2002 | EP1222289A2 Chimeric immunogenic compositions and nucleic acids encoding them |
| 07/17/2002 | EP1222279A2 Growth factor polypeptides and nucleic acids encoding same |
| 07/17/2002 | EP1222277A2 Endozepine-like polypeptides and polynucleotides encoding same |
| 07/17/2002 | EP1222267A2 Pcna-associated cell cycle proteins, compositions and methods of use |
| 07/17/2002 | EP1222266A2 Pca3 messenger rna species in benign and malignant prostate tissues |
| 07/17/2002 | EP1222264A1 Human sit4 associated proteins like (sapl) proteins and encoding genes; uses thereof |
| 07/17/2002 | EP1222260A1 Preparation of cellular components that are substantially free of chromosomal dna |
| 07/17/2002 | EP1222255A1 Polypeptide fragments comprising c-terminal portion of helicobacter catalase |
| 07/17/2002 | EP1222251A1 Ex vivo generation of functional osteoclasts from bone marrow in a three-dimensional bioreactor |
| 07/17/2002 | EP1222211A1 Pcna associated cell cycle proteins, compositions and methods of use |
| 07/17/2002 | EP1222209A2 Modulation of t cell differentiation for the treatment of t helper cell mediated diseases |
| 07/17/2002 | EP1222208A1 Polypeptide derivatives of parathyroid hormone (pth) |
| 07/17/2002 | EP1222206A1 Pablo, a polypeptide that interacts with bcl-xl, and uses related thereto |
| 07/17/2002 | EP1222203A1 Method of altering polypeptide aggregation |
| 07/17/2002 | EP1222201A2 Peptides which stimulate the immune response and tissue regeneration |
| 07/17/2002 | EP1222193A2 Imidazole derivatives as phosphodiesterase vii inhibitors |
| 07/17/2002 | EP1222192A1 Hexahydrofuro[2,3-b]furan-3-yl-n- 3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropyl carbamate as retroviral protease inhibitor |
| 07/17/2002 | EP1222191A2 Benzodiazepin derivatives, the production and use thereof |
| 07/17/2002 | EP1222188A1 Novel imidazopyridine carbonitrile compounds |
| 07/17/2002 | EP1222187A2 Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| 07/17/2002 | EP1222186A2 Condensed naphthyridines as hiv reverse transcriptase inhibitors |
| 07/17/2002 | EP1222185A1 Tetrahydrobenzindolone derivatives, their preparation and their use as 5-ht7 receptor antagonists |
| 07/17/2002 | EP1222183A1 Benzopyran derivatives |
| 07/17/2002 | EP1222182A2 Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benozopyrans |
| 07/17/2002 | EP1222175A1 4,5-disubstituted-2-aminopyrimidines |
| 07/17/2002 | EP1222171A1 Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof |
| 07/17/2002 | EP1222170A1 Novel nicotinonitrile compounds |
| 07/17/2002 | EP1222169A1 Novel trisubstituted pyridine compounds |
| 07/17/2002 | EP1222163A1 2'-substituted 1,1'-biphenyl-2-carbonamides, method for the production thereof, use thereof as a medicament and pharmaceutical preparations containing said compounds |
| 07/17/2002 | EP1221976A1 Low dose ifn-gamma for treatment of disease |
| 07/17/2002 | EP1221974A2 Magnetic targeted carrier |
| 07/17/2002 | EP1221963A1 Methods of inhibiting osteoclastogenesis |
| 07/17/2002 | EP1221962A2 Inhibitors of proteasomal activity for stimulating bone and hair growth |
| 07/17/2002 | EP1221953A1 Treating sleep disorders using desloratadine |